Free tool
FAERS Monitor: Actonel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020835 or its brand name (Actonel, Risedronate Sodium). Reports on generic versions are filed under their own applications.
Reports
30,757
Serious
25,781
84% of reports
Hospitalization
12,456
Death reported
2,978
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- arthralgia3,863
- pain3,826
- drug ineffective3,764
- dyspnoea3,107
- nausea3,083
- fatigue3,043
- vomiting3,040
- off label use2,973
- diarrhoea2,773
- drug hypersensitivity2,687
- pneumonia2,667
- malaise2,504
- rheumatoid arthritis2,467
- headache2,399
- pain in extremity2,174
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,012 |
| 2005 | 1,174 |
| 2006 | 1,044 |
| 2007 | 1,141 |
| 2008 | 1,332 |
| 2009 | 1,656 |
| 2010 | 1,731 |
| 2011 | 1,455 |
| 2012 | 1,813 |
| 2013 | 1,177 |
| 2014 | 902 |
| 2015 | 1,117 |
| 2016 | 1,124 |
| 2017 | 898 |
| 2018 | 930 |
| 2019 | 1,240 |
| 2020 | 1,521 |
| 2021 | 1,401 |
| 2022 | 1,647 |
| 2023 | 1,672 |
| 2024 | 1,911 |
| 2025 | 1,780 |
| 2026 | 1,078 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,402 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 2,467 | 15.2 | 14.6 | 32,097 |
| drug hypersensitivitySignal | 2,687 | 9.6 | 9.3 | 20,633 |
| arthralgiaSignal | 3,863 | 6.4 | 6.2 | 17,797 |
| pneumoniaSignal | 2,667 | 5.7 | 5.5 | 10,332 |
| pain in extremitySignal | 2,174 | 5.1 | 4.9 | 7,158 |
| vomitingSignal | 3,040 | 4.4 | 4.3 | 8,242 |
| painSignal | 3,826 | 4.3 | 4.2 | 9,840 |
| malaiseSignal | 2,504 | 3.9 | 3.8 | 5,530 |
| dyspnoeaSignal | 3,107 | 3.8 | 3.6 | 6,455 |
| diarrhoeaSignal | 2,773 | 2.9 | 2.8 | 3,660 |
| fatigueSignal | 3,043 | 2.7 | 2.6 | 3,311 |
| nauseaSignal | 3,083 | 2.7 | 2.6 | 3,332 |
| headacheSignal | 2,399 | 2.6 | 2.5 | 2,472 |
| off label useSignal | 2,973 | 2.3 | 2.2 | 2,336 |
| drug ineffective | 3,764 | 2.0 | 1.9 | 1,869 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.